Advisory Research’s Cabaletta Bio CABA Stock Holding History

Advisory Research’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17,660	Closed	-$401K	–	186
2023 Q4	$401K	Buy	+17,660	New	+$297K	0.06%	267

Other funds holding CABA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Advisory Research's CABA Position: Q1 2024 in Review

Advisory Research sold out of Cabaletta Bio (CABA) in Q1 2024, closing a stake of 17,660 shares — an estimated $401K sold.

Advisory Research first reported a position in CABA in Q4 2023 and held it in 1 quarter. The position peaked at $401K in Q4 2023. 159 funds tracked by Wall St. Rank hold CABA as of Q1 2024.

Advisory Research reported no remaining Cabaletta Bio position as of Q1 2024 after selling out during the quarter.
Advisory Research sold 17,660 Cabaletta Bio shares in Q1 2024, an estimated $401K.
Advisory Research first reported a position in Cabaletta Bio in Q4 2023 and held it in 1 quarter.
Advisory Research's Cabaletta Bio position peaked at $401K in Q4 2023.
159 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.